Hemoglobin normalization trials in chronic kidney disease: What should we learn about quality of life as an end point?

Journal of Nephrology

Volumn 21, Issue 4, 2008, Pages 478-484

  Covic, Adrian ^a   Seica, Anca ^a   Gusbeth Tatomir, Paul ^a   Goldsmith, David ^b  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Anemia; Chronic kidney disease; Quality of life

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION PROCESSING; PERITONEAL DIALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SHORT FORM 36; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 52649122813     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Harnett JD, Kent GM, Foley RN, Parfrey PS. Cardiac function and hematocrit level. Am J Kidney Dis. 1995;25:S3-S7.
2. Foley RN, Parfrey PS, Kent GM, et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720-1725.
3. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573-578.
4. Powe NR, Griffiths RI, Watson AJ, et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol. 1994;4:1455-1465.
5. Cotter DJ, Stefanik K, Zhang Y, Thamer M. Improved survival with higher hematocrits: where is the evidence? Semin Dial. 2004;17:181-183.
6. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher haemoglobin targets with erythropoietin in haemodialysis patients. Kidney Int. 2003;64:295-330.
7. Paoletti E, Cannella G. Update on erythropoietin treatment: should haemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol. 2006;17:S74-S76.
8. Mikhail A, Goldsmith D. Chronic kidney disease, anaemia, and epoetin. N Engl J Med. 2007;356:956-957.
9. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-388.
10. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
11. Foley RN, Parfrey PS, Morgan J, et al. Effect of haemoglobin levels in haemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-1335.
12. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353-361.
13. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148-156.
14. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anaemia correction in incident haemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-2189.
15. Drueke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med. 2006;355:2071-2084.
16. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anaemia on the progression of CKD. Am J Kidney Dis. 2006;47:738-750.
17. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
18. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757-766.
19. Cagney KA, Wu AW, Fink NE, et al. Formal literature review of quality-of-life instruments used in end-stage renal disease. Am J Kidney Dis. 2000;36:327-336.
20. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006;18:CD003967.
21. O'Connor R. Concepts and definitions in health-related quality of life. In: Measuring quality of life in health. London: Elsevier/Churchill Livingstone; 2004.
22. Revicki DA. Health-related quality of life in the evaluation of medical therapy for chronic illness. J Fam Pract. 1989;29:377-380.
23. Rettig RA, Sadler JH, Meyer KB, et al. Assessing health and quality of life outcomes in dialysis: a report on an Institute of Medicine workshop. Am J Kidney Dis. 1997;30:140-155.
24. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). Med Care. 1992;30:473-483.
25. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19:1-47.
26. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant. 2000;15:23-28.
27. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.